Beijing Aosaikang Pharmaceutical Co., Ltd. (SZSE:002755) agreed to acquire 60% stake in Jiangsu Vedkang Medical Science and Technology Co., Ltd. from Changzhou Beiruishi Enterprise Management Co., Ltd., Changzhou Yisiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin for approximately CNY 830 million on April 22, 2021. Under the terms of consideration, 30% equity of the target company will pay by cash CNY 417 million and the rest 30% will pay by issuing 28.6 million shares, at CNY 14.59 per share, total valued CNY 417 million. Jiangsu Vedkang Medical Science and Technology reported Total revenues of CNY 374.4 million, total assets of CNY 314.9 million, net income of CNY 98 million and Total common equity of CNY 111 million for the year ending December 31, 2020. Changzhou Beiruishi Enterprise Management's shareholder and Changzhou Yisiyuan Enterprise Management Co., Ltd. shareholders approved the deal and as of April 23, 2021, Beijing Aosaikang Pharmaceutical Co., Ltd's board approved the deal. The deal is subject to approval from China Securities Regulatory Commission. As of October 27, 2021, China Securities Regulatory Commission has not approved the transaction this time. Grandall Law Firm acted as legal advisor and BDO China SHU LUN PAN Certified Public Accountants LLP acted as accountant to Beijing Aosaikang Pharmaceutical Co., Ltd. As of July 29, 2021, The transaction has been approved by shareholders of Beijing Aosaikang Pharmaceutical Co., Ltd. As of August 2, 2021, The issue price for the transaction was adjusted from CNY 14.59 per share to CNY 14.39 per share. Total number of shares to be issued as payment is 28,978,455 shares, 12.462501 million shares will be issued to Zhuang Xiaojin, 2.581218 million shares will be issued to Miao Donglin, 9.271341 million shares will be issued to Beiruishi and 4.663395 million shares will be issued to Yisiyuan. Huatai United Securities Co., Ltd. acted as financial advisor to Beijing Aosaikang Pharmaceutical.

Beijing Aosaikang Pharmaceutical Co., Ltd. (SZSE:002755) cancelled the acquisition of Jiangsu Vedkang Medical Science and Technology Co., Ltd. from Changzhou Beiruishi Enterprise Management Co., Ltd., Changzhou Yisiyuan Enterprise Management Co., Ltd., Zhuang Xiaojin and Miao Donglin on April 17, 2022.